| |
Treg < 15
|
Treg ≥15
|
P-value
|
|---|
|
Tumour size (mm)
| | | |
|---|
|
Median
|
21.2
|
23.8
|
0.571
|
|
Tumour grade
| | |
< 0.001
|
|
1
|
56 (22%)
|
25 (11%)
| |
|
2
|
123 (47%)
|
84 (38%)
| |
|
3
|
80 (31%)
|
115 (51%)
| |
|
Nodal status
| | |
0.062
|
|
Negative
|
154 (59%)
|
109 (51%)
| |
|
Positive
|
107 (41%)
|
107 (49%)
| |
|
ER
| | |
0.025
|
|
Negative
|
73 (28%)
|
81 (38%)
| |
|
Positive
|
189 (72%)
|
135 (62%)
| |
|
HER2
| | |
0.002
|
|
Negative
|
238 (97%)
|
186 (90%)
| |
|
Positive
|
7 (3%)
|
20 (10%)
| |
|
CXCL12
| | |
0.008
|
|
Negative
|
51 (41%)
|
27 (25%)
| |
|
Positive
|
74 (59%)
|
83 (75%)
| |
|
Endocrine Rx
| | |
0.255
|
|
Negative
|
99 (37%)
|
72 (32%)
| |
|
Positive
|
167 (63%)
|
151 (68%)
| |
|
Chemotherapy
| | |
0.148
|
|
Negative
|
168 (64%)
|
127 (57%)
| |
|
Positive
|
96 (35%)
|
95 (43%)
| |
- ER, estrogen receptor; Rx, therapy.
